… of the OATP substrate fexofenadine, suggesting that other constituents contribute to the
effect of whole juice 15. A second clinical study involving a modified grapefruit juice devoid of …

… While the main focus of our review was P-gp induction, we also noted that the exposure
of pravastatin, an OATP substrate, was reduced by a similar extent as that for dabigatran …

… , drug interactions between ketoconazole and substrate drugs could occur without a clear
understanding of the underlying mechanisms. The inhibitory potential of ketoconazole on the …

… When perpetrator interactions were assessed, … CYP3A substrates, whereas paritaprevir (an
OATP1B1/1B3 inhibitor) greatly increased the exposure of sensitive OATP1B1/1B3 substrates…

… substrate drugs.75 The limitation of fexofenadine as a P-gp probe is the involvement of OATPs
(OATP2B1 and OATP1B1/… a P-gp probe only when OATPs/OAT3 inhibition is not involved …

… substrate for in vitro drug interaction studies. The remarkably potent inhibition of OATP1B1
… relevant drug interactions between lopinavir and OATP1B substrates such as fexofenadine. …

… of OATP substrates, we used bosentan as a case example. The rapid-equilibrium model
cannot recover the observed biphasic human pharmacokinetic profile of bosentan, whereas the …

… , monitoring drug interaction with OATP1B1/3 and ABC proteins is recommended. Our aim
was to assess the interaction of recently identified fluorescent OATP substrates (various dyes …

… relevance of drug interactions involving lipid-lowering drugs, … interaction risk also increases
if inhibitors of both CYP3A4 and OATP1B1 are coadministered with their joint substrates …

… and OATP substrate, then single-dose rifampin can increase an NME’s exposure via inhibition
of OATP… may be masked by coadministration with an OATP substrate. The net steady-state …